# Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

> **NCT03827473** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 1 (actual)

## Conditions studied

- Castration-Sensitive Prostate Carcinoma
- Metastatic Prostatic Adenocarcinoma
- Stage IV Prostate Cancer
- Stage IVA Prostate Cancer
- Stage IVB Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Antiandrogen Therapy
- **DRUG:** Docetaxel
- **DRUG:** Prednisone
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03827473
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-08
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The trial was closed because the changing standard of care landscape, making this trial not impactful anymore.
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827473, "Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03827473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*